BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/31/2015 1:27:00 PM | Browse: 1259 | Download: 2023
 |
Received |
|
2015-06-08 10:46 |
 |
Peer-Review Started |
|
2015-06-11 09:10 |
 |
To Make the First Decision |
|
2015-07-14 12:01 |
 |
Return for Revision |
|
2015-07-27 19:47 |
 |
Revised |
|
2015-08-11 22:44 |
 |
Second Decision |
|
2015-10-16 13:12 |
 |
Accepted by Journal Editor-in-Chief |
|
2015-10-19 09:04 |
 |
Accepted by Executive Editor-in-Chief |
|
2015-10-26 17:57 |
 |
Articles in Press |
|
2015-10-26 17:57 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2015-12-11 15:47 |
 |
Publish the Manuscript Online |
|
2015-12-31 13:27 |
ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
|
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Topic Highlights |
Article Title |
Current status and perspectives of immune-based therapies for hepatocellular carcinoma
|
Manuscript Source |
Invited Manuscript |
All Author List |
Maridi Aerts, Daphné Benteyn, Hans Van Vlierberghe, Kris Thielemans and Hendrik Reynaert |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
Kankerplan Action 29, Ministry of health |
to Aerts M |
Flemish Fund for Research (FWO) |
|
|
Corresponding Author |
Hendrik Reynaert, MD, PhD, Professor, University hospital, UZ Brussel, Department of Gastroenterology and Hepatology, Laarbeeklaan 101, 1090 Brussels,
Belgium. hendrik.reynaert@uzbrussel.be
|
Key Words |
Hepatocellular carcinoma; Immunotherapy; Dendritic cells; Dendritic cell vaccination; Therapy |
Core Tip |
Hepatocellular carcinoma is a frequent cancer with a high mortality. For early stage cancer there are potentially curative treatments including local ablation, resection and liver transplantation. However, recurrence or development of a new tumor after treatment are not uncommon. Moreover, for more advanced stage disease, there is no optimal treatment available. Thus, there is an urgent need for novel and effective therapies for advanced stage hepatocellular carcinoma, and to prevent and to treat recurrence after local treatment of hepatocellular carcinoma.
|
Publish Date |
2015-12-31 13:27 |
Citation |
Aerts M, Benteyn D, Van Vlierberghe H, Thielemans K, Reynaert H. Current status and perspectives of immune-based therapies for hepatocellular carcinoma. World J Gastroenterol 2016; 22(1): 253-261 |
URL |
http://www.wjgnet.com/1007-9327/full/v22/i1/253.htm |
DOI |
http://dx.doi.org/10.3748/wjg.v22.i1.253 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345